NEW YORK (GenomeWeb News) – Investment bank Goldman Sachs has reinstated coverage of Illumina, giving it a Neutral rating and a 12-month price target on its stock of $48.
The bank suspended coverage of Illumina shortly after Roche launched its hostile bid for the San Diego firm. Goldman Sachs was an advisor to Illumina on the proposed deal, which ended when Roche abandoned its pursuit last month.